Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EQL Pharma AB ( (SE:EQL) ) has provided an update.
EQL Pharma AB has received marketing approval in Germany for its key product, methenamine hippurate, branded as Cystohipp, which will be launched in mid-2026. This product provides German patients with recurrent urinary tract infections a non-antibiotic alternative, addressing a significant need for treatments that do not contribute to antibiotic resistance. The market potential is optimistic, with expectations of rapid growth due to the clear demand for such alternatives.
More about EQL Pharma AB
EQL Pharma AB is a company that specializes in the development and sale of generic drugs, which are medically equivalent to original drugs. The company focuses on niche generics with limited competition and operates primarily in the Nordic and European markets, with a strong emphasis on prescription drugs, including hospital products. EQL Pharma AB is based in Lund and is listed on the Nasdaq Stockholm stock market. The company collaborates with leading contract manufacturers and major pharmaceutical companies in the EU and Asia.
Average Trading Volume: 51,857
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.54B
For an in-depth examination of EQL stock, go to TipRanks’ Overview page.